“We are excited to see our dd-cfDNA technology demonstrate strong predictive value for AMR, supporting clinicians in identifying AMR in patients sooner, thereby enhancing the opportunity for better outcomes. The trial’s results further validate dd-cfDNA as a critical biomarker that can bridge diagnostic gaps for transplant patients.”
Oncocyte Chief Science Officer Dr. Ekkehard Schuetz
"This study underscores the impact of dd-cfDNA as a critical biomarker for early AMR detection, providing healthcare teams with timely data enabling them to initiate treatments sooner."
Dr. Aylin Akifova, first author from Charité
“We congratulate Charité’s research teams on these compelling findings, which further underscore our mission to empower clinicians with tools for precision diagnostics while also democratizing access to novel molecular diagnostic testing to improve patient outcomes. We look forward to expanding the clinical applications of dd-cfDNA technology and supporting transplant communities worldwide with our innovative diagnostic solutions.”
Josh Riggs, CEO of Oncocyte
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/